JPS6126800B2 - - Google Patents
Info
- Publication number
- JPS6126800B2 JPS6126800B2 JP52125882A JP12588277A JPS6126800B2 JP S6126800 B2 JPS6126800 B2 JP S6126800B2 JP 52125882 A JP52125882 A JP 52125882A JP 12588277 A JP12588277 A JP 12588277A JP S6126800 B2 JPS6126800 B2 JP S6126800B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- product
- composition according
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 5
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 2
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 239000002569 water oil cream Substances 0.000 claims description 2
- 150000008495 β-glucosides Chemical class 0.000 claims description 2
- 229940124452 immunizing agent Drugs 0.000 claims 2
- 239000000047 product Substances 0.000 description 21
- 239000002671 adjuvant Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001698 pyrogenic effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- GAWAYYRQGQZKCR-REOHCLBHSA-N (S)-2-chloropropanoic acid Chemical compound C[C@H](Cl)C(O)=O GAWAYYRQGQZKCR-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- AEFLONBTGZFSGQ-GSVOUGTGSA-N D-isoglutamine Chemical class NC(=O)[C@H](N)CCC(O)=O AEFLONBTGZFSGQ-GSVOUGTGSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- -1 benzyl ester Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7631935A FR2368282A1 (fr) | 1976-10-22 | 1976-10-22 | Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5353628A JPS5353628A (en) | 1978-05-16 |
| JPS6126800B2 true JPS6126800B2 (enExample) | 1986-06-21 |
Family
ID=9179110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12588277A Granted JPS5353628A (en) | 1976-10-22 | 1977-10-21 | Nnacetyllmuramyllllalanylldd isogultamine ppaminophenyl derivatives* and immunological adjant containing said compound and process for preparation thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4185089A (enExample) |
| JP (1) | JPS5353628A (enExample) |
| CH (1) | CH626629A5 (enExample) |
| DE (1) | DE2747379A1 (enExample) |
| FR (1) | FR2368282A1 (enExample) |
| GB (1) | GB1590659A (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2428051A1 (fr) * | 1978-06-05 | 1980-01-04 | Anvar | Nouveaux composes du type muramyl-peptide et medicaments les contenant |
| US4377570A (en) * | 1979-01-29 | 1983-03-22 | Merck & Co., Inc. | Immunologically active dipeptidyl saccharides and methods of preparation |
| FR2449697A1 (fr) | 1979-02-20 | 1980-09-19 | Anvar | Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant |
| FI75578C (fi) * | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5149529A (en) * | 1988-04-08 | 1992-09-22 | Board Of Trustees Of Leland Chiron Corporation | Compositions and treatment for herpes simplex |
| US4950645A (en) * | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US5416070A (en) * | 1988-07-08 | 1995-05-16 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| RU2083588C1 (ru) * | 1995-09-11 | 1997-07-10 | Безруков Михаил Васильевич | Способ получения мурамилпептидов |
| AUPR079700A0 (en) | 2000-10-17 | 2000-11-09 | Alchemia Pty Ltd | Combinatorial libraries of monosaccharides |
| AU2004262506A1 (en) | 2003-02-28 | 2005-02-17 | National Institutes Of Health | Compositions, methods and kits relating to poxvirus subunit vaccines |
| WO2006112869A2 (en) * | 2004-07-19 | 2006-10-26 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| MX2007015639A (es) * | 2005-06-08 | 2008-02-15 | Newbiomed Pika Pte Ltd | Adyuvante basado en acido poliinosinico-acido policitidilico. |
| CN101501055B (zh) * | 2005-06-23 | 2016-05-11 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| US8367052B2 (en) | 2007-03-26 | 2013-02-05 | General Regeneratives Holdings Inc. | Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies |
| EP2222344A4 (en) * | 2007-11-30 | 2012-11-07 | Baylor College Medicine | VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE |
| US9808504B2 (en) | 2009-09-22 | 2017-11-07 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
| KR101955365B1 (ko) | 2011-07-12 | 2019-03-07 | 필라델피아 헬스 앤드 에듀케이션 코포레이션 디/비/에이 드렉셀 유니버시티 컬리지 오브 메디슨 | 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신 |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
| CN106163554B (zh) | 2014-12-23 | 2021-09-07 | 依生生物制药(新加坡)私人有限公司 | 一种包含pika佐剂的狂犬病组合物 |
| WO2016138286A1 (en) | 2015-02-26 | 2016-09-01 | Stc.Unm | Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
| WO2020140007A1 (en) | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| WO2025096754A1 (en) | 2023-10-31 | 2025-05-08 | Musc Foundation For Research Development | The use of enolase inhibitor pomhex for treatment of fibrosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082736A (en) * | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
| US4082735A (en) * | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
-
1976
- 1976-10-22 FR FR7631935A patent/FR2368282A1/fr active Granted
-
1977
- 1977-10-20 CH CH1280977A patent/CH626629A5/fr not_active IP Right Cessation
- 1977-10-21 GB GB43832/77A patent/GB1590659A/en not_active Expired
- 1977-10-21 JP JP12588277A patent/JPS5353628A/ja active Granted
- 1977-10-21 DE DE19772747379 patent/DE2747379A1/de not_active Ceased
- 1977-10-25 US US05/845,105 patent/US4185089A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5353628A (en) | 1978-05-16 |
| DE2747379A1 (de) | 1978-04-27 |
| US4185089A (en) | 1980-01-22 |
| FR2368282A1 (fr) | 1978-05-19 |
| GB1590659A (en) | 1981-06-03 |
| FR2368282B1 (enExample) | 1980-10-17 |
| CH626629A5 (enExample) | 1981-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6126800B2 (enExample) | ||
| US4094971A (en) | Immunological adjuvant agents active in aqueous solution | |
| DE68917126T2 (de) | T-zellen-epitope als träger für einen konjugierten impfstoff. | |
| Goodfriend et al. | Antibodies to bradykinin and angiotensin: a use of carbodiimides in immunology | |
| DE69017149T2 (de) | Synthetische Peptide nützlich als universale Träger für die Herstellung von immunogenischen Konjugaten und deren Benützung in der Entwicklung von synthetischen Impfstoffen. | |
| US4401592A (en) | Pharmaceutical composition having antitumor activity | |
| DE60011571T2 (de) | Verbindungen mit immunologischem adjuvanseffekt | |
| SK11295A3 (en) | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them | |
| US4153684A (en) | Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives | |
| EP0003833B1 (de) | Antigenderivate, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate | |
| US4158052A (en) | Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-isoglutamine | |
| JPH06500772A (ja) | 改良されたワクチン組成物 | |
| US4220637A (en) | Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents | |
| US4427659A (en) | Muramyl peptide substituted on a peptide nitrogen and medicaments containing the same | |
| JP2002536384A (ja) | Ｔヘルパー細胞エピトープ | |
| DE69530380T2 (de) | Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik | |
| DE60127113T2 (de) | Gd3-mimetische peptide | |
| US4101649A (en) | Hydrosoluble agents having non specific immunodepressive properties | |
| RU2124022C1 (ru) | Фуллереновое производное гликопептида, обладающее адъювантной активностью | |
| SU1326197A3 (ru) | Способ получени N-ацетилмурамилпептидов | |
| CA1333563C (en) | Synthetic vaccine against foot and mouth disease and a process for the preparation thereof | |
| US4172125A (en) | Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-glutamic acid and method of use | |
| JPH0137399B2 (enExample) | ||
| EP0135788A1 (en) | Muramyldipeptide active ester derivatives | |
| GB1584791A (en) | Muromyl peptide immunological adjuvants |